S-743229 is a combination of the investigational beta-lactamase inhibitor xeruborbactam (delivered orally as a prodrug) with ceftibuten, a beta-lactam antibiotic discovered by Shionogi.1,2 Combinations of beta-lactam antibiotics and beta-lactamase inhibitors have become an important strategy to overcome emerging resistance to new drugs.3 S-743229 is an investigational oral drug being studied for potential use in settings where intravenous therapy is not possible or desirable. Building upon the Qpex-validated beta-lactamase inhibitor technology that led to FDA approval of the first treatment in this new drug class, S-743229 is designed to deliver xeruborbactam to treat infections that occur in both the outpatient and inpatient setting.
These compounds and their uses are investigational and have not all been approved by the U.S. Food and Drug Administration. This information is presented only for purposes of providing a general overview and should not be construed as a recommendation for use of any product for unapproved uses.
References
- Long-term commitment to improving R&D to provide novel treatments for infectious diseases. Shionogi & Co., Ltd. Accessed February 13, 2025. Available at: https://www.shionogi.com/global/en/sustainability/amr/commitment.html. โฉ๏ธ
- Lomovskaya O, Rubio-Aparicio D, Tsivkovski R, Loutit J, Dudley M. The Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 Restores the Potency of Multiple Oral Beta-Lactam Antibiotics against Beta-Lactamase-Producing Strains of Resistant Enterobacterales. Antimicrobial Agents and Chemotherapy. 2022 Feb 15;66(2):e0216821. doi:10.1128/AAC.02168-21. โฉ๏ธ
- Abodakpi H, et al. What the Clinical Microbiologist Should Know About Pharmacokinetics/Pharmacodynamics in the Era of Emerging Multidrug Resistance: Focusing on ฮฒ-Lactam/ฮฒ-Lactamase Inhibitor Combinations. Clin Lab Med. 2019 Sep;39(3):473-485. doi:10.1016/j.cll.2019.05.006. โฉ๏ธ